The Translational Drug Discovery Group (TDDG) was established in 2011 as part of a strategic investment by the University of Sussex in the School of Life Sciences. The group comprises medicinal chemistry and molecular pharmacology laboratories and aims to translate a fundamental understanding of disease processes and molecular targets into novel drugs. Research is currently focussed on:
Oncology – working with the Sussex Genome Damage & Stability Centre and external partners the group has a developing portfolio of novel programs targeting DNA damage repair targets.
Neuroscience – the group has a strong track record in neuroscience drug discovery and has several programs ranging from early hit to lead to late stage optimisation for indications including schizophrenia, pain and anxiety.
Respiratory – activities are focused upon diseases associated with epithelial dysfunction including cystic fibrosis, COPD and asthma.
Ion channels – the group has considerable expertise in prosecuting ion channel targets and has specialist capabilities including electrophysiology and bespoke compound library generation.
Principal Disease Indication(s)
Oncology, Neuroscience, Respiratory
Structure-based drug discovery, Ion channel modulators
Biophysical, X-ray crystallography, virtual screening, high-throughput electrophysiology, automated synthesis, medicinal chemistry
Wellcome Trust, Cancer Research UK, Medical Research Council, EU, Migraine Research Foundation, Alzheimer’s Trust, Janssen, Evotec, Essen, Novartis
Number of Screens / year (any size):
Medicinal Chemistry Follow-up:
Dr Paul Beswick
Phone: +44 (0)1273 873 155